News

(SEATTLE), April 20, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it has expanded its partnership with Rocket Pharmaceuticals, a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders.

(CHIBA), April 8, 2021 – AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced the appointment of Jun Takami as the General Manager/Site Head, to lead the continued successful operations as well as continuous improvements at its Chiba, Japan site.

(SEATTLE) April 5, 2021 -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced it will be attending Alliance for Regenerative Medicine’s virtual Meeting on the Mediterranean conference this week, from April 6 – 9, 2021 as a first-time attendee and Gold- and Agenda-level sponsor.